A study of hepatocellular carcinoma patients surviving for 10 years—Comparison of hepatectomy and percutaneous ablation therapy—

Kioka Kiyohide; Kawasaki Yasuko; Nakai Takashi; Shimizu Sadatoshi; Kanazawa Akishige; Tsukamoto Tadashi; Kurai Osamu; Oka Hiroko; Yamasaki Osamu

doi:10.3380/jmicrowavesurg.27.65

Primary Hepatic Carcinoma

A study of hepatocellular carcinoma patients surviving for 10 years—Comparison of hepatectomy and percutaneous ablation therapy—

Kiyohide Kioka, Yasuko Kawasaki, Takashi Nakai, Sadatoshi Shimizu, Akishige Kanazawa, Tadashi Tsukamoto, Osamu Kurai, Hiroko Oka, Osamu Yamasaki

Author information

Kiyohide Kioka
Department of Hepatology, Osaka City General Hospital
Yasuko Kawasaki
Department of Hepatology, Osaka City General Hospital
Takashi Nakai
Department of Hepatology, Osaka City General Hospital
Sadatoshi Shimizu
Department of Hepatobilliary and Pancreatic Surgery, Osaka City General Hospital
Akishige Kanazawa
Department of Hepatobilliary and Pancreatic Surgery, Osaka City General Hospital
Tadashi Tsukamoto
Department of Hepatobilliary and Pancreatic Surgery, Osaka City General Hospital
Osamu Kurai
Department of Gastroenterology and Hepatology, Juso Municipal Hospital
Hiroko Oka
Department of Gastroenterology and Hepatology, Juso Municipal Hospital
Osamu Yamasaki
Department of Gastroenterology and Surgery, Juso Municipal Hospital

Keywords: 10-year survival, hepatocellular carcinoma, percutaneous microwave coagulation therapy (PMCT), percutaneous ethanol injection therapy (PEIT), hepatectomy

JOURNAL FREE ACCESS

2009 Volume 27 Pages 65-70

DOI https://doi.org/10.3380/jmicrowavesurg.27.65

Details

Abstract

We examined the characteristics of hepatocellular carcinoma patients with 10-year survival who had received initial treatment and been followed up for more than 10 years at our hospital. The 10-year survival rate was 12%, and comparison of patients who survived for 10 years (n = 36) and those who did not (n = 265) showed that the former had better hepatic functional reserve, with mild tumor progression and rates of usage of post-treatment interferon therapy and performance of hepatectomy. Comparison of patients with hepatectomy (n = 24) and those with percutaneous ablation therapy (n = 10) who survived for 10 years showed that those with hepatectomy had lower total bilirubin values, higher platelet counts, and larger tumor diameters. The total number of treatments in patients with tumor recurrence who survived for 10 years was 9.6 ± 5.2 in the case of hepatectomy and 14.6 ± 8.0 in the case of percutaneous ablation therapy. These findings suggest that repeated treatment can lead to long-term survival in patients with good hepatic functional reserve in whom initial treatment is radical and in whom subsequent periodic follow-up yields early detection of tumor recurrences.

Corresponding author

Register with J-STAGE for free!